Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Over the past two years, demand for GLP-1 drugs has surged. Medications like Ozempic, Wegovy, and Zepbound are not only ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

California Healthline: Silence On E. Coli Outbreak Highlights How Trump Team’s Changes Undermine Food Safety Food ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Drugmakers are introducing discounts and lower-cost options for consumers who have to pay for GLP-1 drugs out of pocket. News outlets look at the trend in pricing for drugs like Wegovy and Zepbound.

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...